These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 7913497)

  • 1. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.
    Decker MW; Brioni JD; Sullivan JP; Buckley MJ; Radek RJ; Raszkiewicz JL; Kang CH; Kim DJ; Giardina WJ; Wasicak JT
    J Pharmacol Exp Ther; 1994 Jul; 270(1):319-28. PubMed ID: 7913497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.
    Arneric SP; Sullivan JP; Briggs CA; Donnelly-Roberts D; Anderson DJ; Raszkiewicz JL; Hughes ML; Cadman ED; Adams P; Garvey DS
    J Pharmacol Exp Ther; 1994 Jul; 270(1):310-8. PubMed ID: 7518514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anxiolytic-like effects of the novel cholinergic channel activator ABT-418.
    Brioni JD; O'Neill AB; Kim DJ; Buckley MJ; Decker MW; Arneric SP
    J Pharmacol Exp Ther; 1994 Oct; 271(1):353-61. PubMed ID: 7965735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.
    Arneric SP; Sullivan JP; Decker MW; Brioni JD; Bannon AW; Briggs CA; Donnelly-Roberts D; Radek RJ; Marsh KC; Kyncl J
    Alzheimer Dis Assoc Disord; 1995; 9 Suppl 2():50-61. PubMed ID: 8534424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
    Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
    J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of [3H]ABT-418: a novel cholinergic channel ligand.
    Anderson DJ; Williams M; Pauly JR; Raszkiewicz JL; Campbell JE; Rotert G; Surber B; Thomas SB; Wasicak J; Arneric SP
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1434-41. PubMed ID: 7791118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors.
    Bontempi B; Whelan KT; Risbrough VB; Lloyd GK; Menzaghi F
    Neuropsychopharmacology; 2003 Jul; 28(7):1235-46. PubMed ID: 12700710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.
    Lin NH; Gunn DE; Ryther KB; Garvey DS; Donnelly-Roberts DL; Decker MW; Brioni JD; Buckley MJ; Rodrigues AD; Marsh KG; Anderson DJ; Buccafusco JJ; Prendergast MA; Sullivan JP; Williams M; Arneric SP; Holladay MW
    J Med Chem; 1997 Jan; 40(3):385-90. PubMed ID: 9022806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABT-418: discriminative stimulus properties and effect on ventral tegmental cell activity.
    Brioni JD; Kim DJ; Brodie MS; Decker MW; Arneric SP
    Psychopharmacology (Berl); 1995 Jun; 119(4):368-75. PubMed ID: 7480515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.
    Bannon AW; Decker MW; Curzon P; Buckley MJ; Kim DJ; Radek RJ; Lynch JK; Wasicak JT; Lin NH; Arnold WH; Holladay MW; Williams M; Arneric SP
    J Pharmacol Exp Ther; 1998 May; 285(2):787-94. PubMed ID: 9580627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3')quinuclidine, an M1 selective cholinergic agonist, attenuates cognitive dysfunctions in an animal model of Alzheimer's disease.
    Fisher A; Brandeis R; Karton I; Pittel Z; Gurwitz D; Haring R; Sapir M; Levy A; Heldman E
    J Pharmacol Exp Ther; 1991 Apr; 257(1):392-403. PubMed ID: 2019998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys.
    Decker MW; Bannon AW; Curzon P; Gunther KL; Brioni JD; Holladay MW; Lin NH; Li Y; Daanen JF; Buccafusco JJ; Prendergast MA; Jackson WJ; Arneric SP
    J Pharmacol Exp Ther; 1997 Oct; 283(1):247-58. PubMed ID: 9336330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
    Sullivan JP; Donnelly-Roberts D; Briggs CA; Anderson DJ; Gopalakrishnan M; Xue IC; Piattoni-Kaplan M; Molinari E; Campbell JE; McKenna DG; Gunn DE; Lin NH; Ryther KB; He Y; Holladay MW; Wonnacott S; Williams M; Arneric SP
    J Pharmacol Exp Ther; 1997 Oct; 283(1):235-46. PubMed ID: 9336329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
    Feuerbach D; Lingenhoehl K; Olpe HR; Vassout A; Gentsch C; Chaperon F; Nozulak J; Enz A; Bilbe G; McAllister K; Hoyer D
    Neuropharmacology; 2009 Jan; 56(1):254-63. PubMed ID: 18793655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.
    Zhu CZ; Chin CL; Rustay NR; Zhong C; Mikusa J; Chandran P; Salyers A; Gomez E; Simler G; Lewis LG; Gauvin D; Baker S; Pai M; Tovcimak A; Brown J; Komater V; Fox GB; Decker MW; Jacobson PB; Gopalakrishnan M; Lee CH; Honore P
    Biochem Pharmacol; 2011 Oct; 82(8):967-76. PubMed ID: 21620806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist.
    Damaj MI; Creasy KR; Welch SP; Rosecrans JA; Aceto MD; Martin BR
    Psychopharmacology (Berl); 1995 Aug; 120(4):483-90. PubMed ID: 8539331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization.
    Lippiello PM; Bencherif M; Gray JA; Peters S; Grigoryan G; Hodges H; Collins AC
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1422-9. PubMed ID: 8968367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a novel cholinergic ion channel agonist SIB-1765F on locomotor activity in rats.
    Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
    J Pharmacol Exp Ther; 1997 Jan; 280(1):384-92. PubMed ID: 8996219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines.
    Cryan JF; Kelly PH; Chaperon F; Gentsch C; Mombereau C; Lingenhoehl K; Froestl W; Bettler B; Kaupmann K; Spooren WP
    J Pharmacol Exp Ther; 2004 Sep; 310(3):952-63. PubMed ID: 15113848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intra-amygdala injection of nicotine and GABA receptor agents on anxiety-like behaviour in rats.
    Zarrindast MR; Solati J; Oryan S; Parivar K
    Pharmacology; 2008; 82(4):276-84. PubMed ID: 18849647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.